申请人:CVIE Therapeutics Limited
公开号:EP3599243A1
公开(公告)日:2020-01-29
Disclosed are compounds of formula (I)
wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; said carbocyclic or heterocyclic ring being optionally substituted with amino (C1-C4) linear or branched alkyl or guanidine or guanidino (C1-C4) linear or branched alkyl;
with the proviso that the heterocycle ring is not furyl;
n is 0 or 1;
R is H or OH;
the dotted line represents an optional double bond C=C; the thick line represents a bond in the β configuration; the wavy line represents a bond both in the α and β configuration;
their enantiomeric and/or diastereomeric mixtures, their pharmaceutically acceptable salts, their solvates, hydrates; their metabolite and metabolic precursors.
The compounds of formula (I) are for use as medicaments, in particular for the treatment of acute or chronic heart failure. Oral administration is also possible.
披露了公式(I)的化合物
其中X,Y,Z是包含在五元碳环或杂环中的环原子,选自由CH,NH,N,O,S组成的组;所述碳环或杂环可任选地被氨基(C1-C4)直链或支链烷基或胍或胍基(C1-C4)直链或支链烷基取代;
条件是杂环不是呋喃基;
n是0或1;
R是H或OH;
虚线代表任选的双键C=C;粗线代表β构型的键;波浪线代表α和β构型的键;
它们的对映异构体和/或对映异构体混合物,它们的药用可接受盐,它们的溶剂化物,水合物;它们的代谢物和代谢前体。
公式(I)的化合物用于作为药物,特别用于治疗急性或慢性心力衰竭。也可以口服给药。